drugset / Trial / NCT00144833
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprenavir/ritonavir to an increased dose of boosted fosamprenavir and to a combination of fosamprenavir (increased dose)/lopinavir/ritonavir.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped: “Incomplete data”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosamprenavir | Small molecule | 700 mg | — |
| Subject | Fosamprenavir | Small molecule | 1400 mg | — |
| Subject | Lopinavir | Other / unclassified | 533 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |
Indications
No indication recorded.